Cytosorbents Corporation
CTSO
$1.11
-$0.0163-1.44%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.39M | 9.89M | 9.79M | 8.67M | 8.81M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.39M | 9.89M | 9.79M | 8.67M | 8.81M |
| Cost of Revenue | 4.11M | 3.39M | 3.22M | 3.36M | 3.20M |
| Gross Profit | 5.28M | 6.50M | 6.57M | 5.31M | 5.61M |
| SG&A Expenses | 7.76M | 8.22M | 9.25M | 10.10M | 9.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.72M | 13.13M | 14.71M | 17.55M | 15.98M |
| Operating Income | -4.33M | -3.23M | -4.93M | -8.88M | -7.17M |
| Income Before Tax | -2.33M | -4.14M | -6.36M | -6.65M | -9.19M |
| Income Tax Expenses | -- | -- | -- | -813.70K | -- |
| Earnings from Continuing Operations | -2.33M | -4.14M | -6.36M | -5.83M | -9.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.33M | -4.14M | -6.36M | -5.83M | -9.19M |
| EBIT | -4.33M | -3.23M | -4.93M | -8.88M | -7.17M |
| EBITDA | -3.95M | -2.83M | -4.53M | -8.49M | -6.76M |
| EPS Basic | -0.04 | -0.08 | -0.12 | -0.13 | -0.21 |
| Normalized Basic EPS | -0.03 | -0.05 | -0.07 | -0.08 | -0.13 |
| EPS Diluted | -0.04 | -0.08 | -0.12 | -0.13 | -0.21 |
| Normalized Diluted EPS | -0.03 | -0.05 | -0.07 | -0.08 | -0.13 |
| Average Basic Shares Outstanding | 54.45M | 54.31M | 54.26M | 46.55M | 44.37M |
| Average Diluted Shares Outstanding | 54.45M | 54.31M | 54.26M | 46.55M | 44.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
